Progesterone sustained release - Catalent/Dare Bioscience
Alternative Names: DARE-FRT1; DARE-PTB1; Estrogen/progesterone intravaginal - Dare Bioscience/Juniper Pharmaceuticals; JNP 0301; Progesterone intravaginal - Dare Bioscience/Juniper PharmaceuticalsLatest Information Update: 10 Sep 2024
At a glance
- Originator Juniper Pharmaceuticals
- Developer Dare Bioscience
- Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pregnancy; Preterm labour
Most Recent Events
- 10 Sep 2024 Progesterone sustained release is still in preclinical development for Pregnancy in USA (Vaginal, Ring)
- 10 Sep 2024 Progesterone sustained release is still in preclinical development for Preterm-labour in USA (Vaginal, Ring)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Pregnancy in USA (Vaginal, Ring)